Alternate promoter burden (APB) high tumours are confirmed with significantly poorer PFS and resistance in gastric cancer patients because of lower T-cell proportion and almost no infiltration into the TME.124 Mutations of key genes involved in the antigen-presenting (MHC I, β2M) and IFN-γ signalling pathway (JAK1/2, IFNγR1/2) may lead to loss of tumour antigen and insensitivity to interferons in tumour cells. The gene discussed is JAK1; the disease is neoplasm.